The trial of Cell free concentrated ascites reinfusion therapy (CART) for patients with massive ascites

(Background)Cancer is most common cause of Japanese death. Massive ascites of refractory and cancer disease give them terrible distress. CART has attention with one of option of active support therapy.(Purpose)We investigate the usefulness of CART with active support therapy.(Method)16 patients who were treated by CART. Analysis items; frequency of CART, disease(benign/malignant), concentration of ascites, Alb/Tp, degree of variability of blood pressure (BP), body temperature (BT), dietary intake, satisfaction level, continuity of chemotherapy(Cx).(Result)Average age (72 year old), gender (N=5/11), benign/malignant (N=4/12), Average course (2.67 times), average ascites (initial/concentrated=3000ml/400ml), Rate of concentration (5.3 times), variability of systolic BP (-5.9%), variability of body temperature=+0.5C, dietary intake volume (+8%), continuity of Cx(N=1). (Discussion)There were no severe adverse event in this study. CART could support patients with massive ascites mildly. However, most of case abandoned chemotherapy. With and without Cx during CART depend on assessment of doctor. (Conclusion)CART should relief intolerable destress and give satisfaction for patients who were in their end of life. Simultaneous cancer chemotherapy and CART is an important topics requiring discussion.